Source:http://linkedlifedata.com/resource/pubmed/id/20043072
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0017262,
umls-concept:C0087111,
umls-concept:C0118975,
umls-concept:C0185117,
umls-concept:C0205281,
umls-concept:C0950521,
umls-concept:C1274040,
umls-concept:C1412517,
umls-concept:C1423613,
umls-concept:C1512083,
umls-concept:C1720675,
umls-concept:C2003941,
umls-concept:C2911684
|
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-12-31
|
| pubmed:abstractText |
Rho-GDIalpha is an inhibitor of Rho-GTPases, which is involved in cancer progression. Little is known about its role in breast cancer progression. There is evidence, that Rho-GDIalpha may modulate drug resistance of breast cancer cells. To assess the importance of Rho-GDIalpha as a risk factor in invasive ductal breast cancer, cancer specimens of three groups of patients were analyzed for Rho-GDIalpha RNA (group 1, N=72 and group 2, N=73) or protein expression (group 3, N=90). In group 1, patients did not receive any adjuvant treatment, whereas, in groups 2 and 3, patients were treated with anti-estrogens and/or with chemotherapeutical drugs. Rho-GDIalpha RNA levels, measured by RT-PCR from fresh-frozen material, did not correlate with relapse-free survival in Kaplan-Meier analysis, except in a subgroup of CMF-only treated patients. In this subgroup, higher Rho-GDIalpha RNA levels were significantly associated with more favorable prognosis. Immunohistochemical analysis (group 3) confirmed the link between higher Rho-GDIalpha expression and better outcome. This was again particularly true for the CMF-only treated patients. Cox regression analysis revealed that high Rho-GDIalpha protein expression reduced the risk for a relapse by approximately 3-fold, even if adjusted for grading, tumor size, nodal and estrogen receptor (ER) status. The data suggest that Rho-GDIalpha is beneficial to patients who received adjuvant chemotherapy. Rho-GDIalpha is possibly a useful biomarker to predict the response of breast cancer patients to CMF treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Guanine Nucleotide Dissociation...,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/rho guanine nucleotide...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1791-2423
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
36
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
379-86
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:20043072-Adult,
pubmed-meshheading:20043072-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20043072-Breast Neoplasms,
pubmed-meshheading:20043072-Carcinoma, Ductal, Breast,
pubmed-meshheading:20043072-Chemotherapy, Adjuvant,
pubmed-meshheading:20043072-Cisplatin,
pubmed-meshheading:20043072-Drug Resistance, Neoplasm,
pubmed-meshheading:20043072-Female,
pubmed-meshheading:20043072-Fluorouracil,
pubmed-meshheading:20043072-Guanine Nucleotide Dissociation Inhibitors,
pubmed-meshheading:20043072-Humans,
pubmed-meshheading:20043072-Immunohistochemistry,
pubmed-meshheading:20043072-Kaplan-Meier Estimate,
pubmed-meshheading:20043072-Methotrexate,
pubmed-meshheading:20043072-Middle Aged,
pubmed-meshheading:20043072-Neoplasm Staging,
pubmed-meshheading:20043072-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20043072-Risk Factors,
pubmed-meshheading:20043072-Treatment Outcome,
pubmed-meshheading:20043072-Tumor Markers, Biological
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.
|
| pubmed:affiliation |
Klinik für Gynäkologie, Universität Halle, Halle, Saale, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|